Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Shattuck Labs, Inc.
Shattuck Labs, Inc.
Hackensack Meridian Health
National Cancer Institute (NCI)
NextCure, Inc.
Novartis
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Incyte Corporation
Incyte Corporation
Incyte Corporation
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb
OHSU Knight Cancer Institute
Amgen
Roswell Park Cancer Institute
Weill Medical College of Cornell University
Celgene
Thomas Jefferson University
M.D. Anderson Cancer Center
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Fred Hutchinson Cancer Center
Celgene
Ensoma
Mayo Clinic
Amgen
M.D. Anderson Cancer Center
Haihe Biopharma Co., Ltd.
Ono Pharmaceutical Co. Ltd
IGF Oncology, LLC
Kyowa Kirin Co., Ltd.
Pfizer
Incyte Corporation
Mayo Clinic
Weill Medical College of Cornell University
Sumitomo Pharma America, Inc.
Swedish Orphan Biovitrum
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Rutgers, The State University of New Jersey
Asana BioSciences
Amgen
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
GlaxoSmithKline
University of Michigan Rogel Cancer Center
Fred Hutchinson Cancer Center